Glycogen Synthase Kinase‐3β as a Central Regulator of Alzheimer's Disease: Mechanistic Insights and Therapeutic Perspectives
European Journal of Neuroscience · 2026-11 · 64 (9)
DOI: 10.1111/ejn.70741 ↗Abstract
ABSTRACT Alzheimer's disease (AD) is a progressive neurological condition marked by cognitive decline, memory impairment, extracellular amyloid‐β (Aβ) accumulation, and intracellular neurofibrillary tangles (NFTs). Among the multiple molecular pathways involved in AD pathogenesis, glycogen synthase kinase‐3β (GSK‐3β) has emerged as a crucial signaling regulator due to its extensive contribution to neuronal survival, synaptic plasticity, metabolism, and cellular stress responses. Growing evidence suggests that abnormal activation of GSK‐3β contributes not merely to classical AD hallmarks, including tau hyperphosphorylation and amyloidogenesis, but is also linked to mitochondrial dysfunction, neuroinflammation, autophagic impairment, ferroptosis, insulin resistance, and oxidative stress through modulation of the Nrf2 pathway. These findings place GSK‐3β as a crucial molecular hub linking different pathogenic pathways in AD. This review outlines the structural attributes along with regulatory mechanisms of GSK‐3β and extensively explores its involvement in AD pathophysiology. Specific emphasis is given to evolving mechanisms, such as metabolic dysregulation, ferroptosis, and antioxidant signaling pathways. Additionally, current breakthroughs in therapeutic targeting techniques such as ATP‐competitive inhibitors, non–ATP‐competitive inhibitors, allosteric modulators, natural chemicals, and clinically studied medicines are emphasized. The translational difficulties linked to selectivity, blood–brain barrier permeability, and clinical efficacies are also explored. Collectively, this review reinforces the therapeutic relevance of GSK‐3β and indicates potential opportunities for creating effective disease‐modifying therapies in AD.
EUVIMED